The Histology Core Facility (HCF) was established in 1990 to provide histology support to researchers doing peer-reviewed cancer research. In addition to providing a variety of techniques, including work with paraffin, methacrylate, cryostat, enzyme histochemistry, and immunohistochemistry, the HCF has expanded to now provide laser capture microdissection (LCM) of paraffin and cryostat sections. Upon request the HCF has addressed special projects, including the embedding and sectioning of whole prostates and large sections of breast as well as serial sectioning of whole ovaries, small tumors, and colonic premalignant lesions. Use of new methodologies by the HCF has led to the acceptance and wider use of these methodologies by the cancer research community in our Cancer Center. The Histology Core Facility has been able to provide routine paraffin and cryostat services to researchers in a week compared to much longer times through a clinical facility. The need for this facility is apparent from its growth rate; the HCF now consistently processes quarterly over seven times the work orders that it received during its first quarter in 1990. The number of users of the HCF that are Cancer Center members continues to increase, and 84 percent of the HCF usage is by Cancer Center members. Many of the techniques provided by the HCF were first developed under the leadership of Thomas G. Pretlow, HCF Director, in the Pretlow research laboratory. Dr. Pretlow is one of nine members of the Scientific Advisory Committee, which directs the HCF. This committee, described in greater detail below, includes users of the HCF from six academic departments and meets approximately every six months to review the performance and policies of the HCF.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA043703-13
Application #
6501436
Study Section
Project Start
1991-09-30
Project End
2006-07-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
13
Fiscal Year
2001
Total Cost
$78,870
Indirect Cost
Name
Case Western Reserve University
Department
Type
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Cummings III, Kenneth C; Zimmerman, Nicole M; Maheshwari, Kamal et al. (2018) Epidural compared with non-epidural analgesia and cardiopulmonary complications after colectomy: A retrospective cohort study of 20,880 patients using a national quality database. J Clin Anesth 47:12-18
Thiagarajan, Praveena S; Sinyuk, Maksim; Turaga, Soumya M et al. (2018) Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase. Nat Commun 9:578
Qiu, Zhaojun; Oleinick, Nancy L; Zhang, Junran (2018) ATR/CHK1 inhibitors and cancer therapy. Radiother Oncol 126:450-464
Elitt, Matthew S; Shick, H Elizabeth; Madhavan, Mayur et al. (2018) Chemical Screening Identifies Enhancers of Mutant Oligodendrocyte Survival and Unmasks a Distinct Pathological Phase in Pelizaeus-Merzbacher Disease. Stem Cell Reports 11:711-726
He, Tian; McColl, Karen; Sakre, Nneha et al. (2018) Post-transcriptional regulation of PIAS3 expression by miR-18a in malignant mesothelioma. Mol Oncol 12:2124-2135
Roche, Kathryn L; Nukui, Masatoshi; Krishna, Benjamin A et al. (2018) Selective 4-Thiouracil Labeling of RNA Transcripts within Latently Infected Cells after Infection with Human Cytomegalovirus Expressing Functional Uracil Phosphoribosyltransferase. J Virol 92:
Bedell, Hillary W; Hermann, John K; Ravikumar, Madhumitha et al. (2018) Targeting CD14 on blood derived cells improves intracortical microelectrode performance. Biomaterials 163:163-173
Nagaraj, A B; Wang, Q Q; Joseph, P et al. (2018) Using a novel computational drug-repositioning approach (DrugPredict) to rapidly identify potent drug candidates for cancer treatment. Oncogene 37:403-414
Somasegar, Sahana; Li, Li; Thompson, Cheryl L (2018) No association of reproductive risk factors with breast cancer tumor grade. Eur J Cancer Prev 27:140-143
Gu, Xiaorong; Ebrahem, Quteba; Mahfouz, Reda Z et al. (2018) Leukemogenic nucleophosmin mutation disrupts the transcription factor hub that regulates granulomonocytic fates. J Clin Invest 128:4260-4279

Showing the most recent 10 out of 1227 publications